About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a publicly listed company based in Burlingame (United States) founded in 2014. Therapeutics are developed for cancers, immune disorders, and infectious diseases. It operates on a HealthTech model. Corvus Pharmaceuticals has raised $87.75 million across 2 funding rounds from investors including Fidelity Investments, TD Securities and Orbimed. The company has 31 employees. Its website corvuspharma.com draws about 14 thousand monthly visits. Corvus Pharmaceuticals offers products and services including Soquelitinib. Its focus areas include Biotechnology and Biopharmaceuticals. Its legal entity is Corvus Pharmaceuticals, Inc. Its competitors include Forty Seven, Compass Therapeutics and Pionyr Immuntherapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Corvus Pharmaceuticals is engaged in the development of novel biopharmaceutical therapies aimed at improving treatments for immune diseases and cancer. The company is based in the biotechnology hub of the San Francisco Bay Area. Its lead program, soquelitinib, is designed as a first-in-class oral therapy to selectively inhibit ITK, modulating critical signaling pathways in the immune system. Research and clinical efforts are directed toward targeting essential cellular elements of the immune system to address unmet medical needs in these sectors.
- Headquarters Burlingame, United States
- Employees 31
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website corvuspharma.com
- Social LinkedIn
- Legal Name Corvus Pharmaceuticals, Inc.
- Net Profit-$15.28 M (USD)75.47as on Dec 31, 2025
- EBITDA-$42.87 M (USD)-56.09as on Dec 31, 2025
- Total Equity Funding$87.75M (USD)
in 2 rounds
- Latest Funding Round$75M (USD), Series B
Sep 2015
- InvestorsFidelity Investments
& 10 more
- Employee Count31
Products & Services of Corvus Pharmaceuticals
Corvus Pharmaceuticals offers a comprehensive portfolio of products and services, including Soquelitinib.
Oral therapy developed to inhibit ITK in immune system.
Funding Insights of Corvus Pharmaceuticals
Corvus Pharmaceuticals has successfully raised a total of $87.75M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.75M
- Total Rounds 2
- Last Round Series B — $75M
- First Round $12.75M
(Dec 2014)
- Investors Count 11
All 2 funding rounds of Corvus Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2015 | $75M | Series B | – | Rock Springs Capital | |
| Dec 2014 | $12.75M | Series A | – | – |
11 investors in total: 11 institutional.
Investors in Corvus Pharmaceuticals
Corvus Pharmaceuticals has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, TD Securities and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private markets investment management with strategies in equity, credit, and secondary investments. | adamsstreetpartners.com | |||
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Corporate-backed venture capital firm focused on the healthcare sector | roche.com/venturefund.htm | |||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
Manages hedge funds with long/short equity and real estate strategies for investors. | 2004 | spherafund.com | Tel Aviv, Israel | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for Corvus Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Corvus Pharmaceuticals
27 people are tracked at Corvus Pharmaceuticals (10 in leadership, 6 in board & advisors, 11 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Richard A. Miller, M.D. | Co-Founder, CEO & President | Leadership |
William Ben Jones | Senior Vice President, Pharmaceutical Development | Leadership |
Leiv Lea | Chief Financial Officer | Leadership |
Lih-Yun Hsu | Director Of Immunology | Leadership |
Cynthia Wilson | Senior Director, Regulatory Affairs | Leadership |
Nicholas Topoian | Vice President, Controller | Leadership |
Jeffrey Arcara | Chief Business Officer | Leadership |
Felicia Flicker | Director, Pharmaceutical Development | Leadership |
Mariem Alrubale | Associate Director, Drug Safety | Leadership |
Otute Akiti | Vice President, CMC | Leadership |
Linda S. Grais | Board Member | Board & advisors |
Ian T. Clark | Board Member | Board & advisors |
Elisha P. Gould | Board Member | Board & advisors |
Scott W. Morrison | Board Member | Board & advisors |
Peter Thompson | Co-Founder | Board & advisors |
Richard A. Miller | Chairman | Board & advisors |
Poorva Ghosh | Scientist II | Team |
James Rosenbaum | SVP, Research | Team |
Nathan Mackowski | Senior Research Associate | Team |
Jenna F. | Purchasing Associate 2 / Clinical Payments Analyst | Team |
7 more people are available in the full profile.
Complete people profiles for Corvus Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Corvus Pharmaceuticals
Corvus Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CRVS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Mar 2016
- Listed onNASDAQ: CRVS
- Listed entityCorvus Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS2210151005
- Share price$9.41 (-6.37% on the day) · 2026-10-13
- Market capitalisation$791.6M
- EPS (diluted, trailing year)$-0.62
- Volume (last session)1,685,656
Financials of Corvus Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$15.3M | -$42.9M | |
| 2024 | -$62.3M | -$27.5M | |
| 2023 | -$27.0M | -$23.3M | |
| 2022 | -$41.3M | -$32.2M | |
| 2021 | -$43.2M | -$38.2M |
Detailed financial statements for Corvus Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Corvus Pharmaceuticals
4 dated milestones of Corvus Pharmaceuticals across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Corvus Pharmaceuticals is founded.
- Funding First funding round of $12.7M.
- Funding Latest funding round, Series B, of $75.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Corvus Pharmaceuticals
Corvus Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Forty Seven, Compass Therapeutics and Pionyr Immuntherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| fortyseveninc.com | 2015 | Palo Alto, United States | $150M | 7,128 | Therapies for diverse diseases including oncology are developed. | |
| compasstherapeutics.com | 2013 | Cambridge, United States | $238.46M | 32 | Therapeutic antibodies for cancer treatment are discovered and developed. | |
| pionyrtx.com | 2015 | San Francisco, United States | $352M | Cancer immunotherapies that target the tumour microenvironment to enhance the body’s antitumour immunity |
Detailed competitors of Corvus Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Corvus Pharmaceuticals
The website of Corvus Pharmaceuticals (corvuspharma.com) receives about 13.6K visits a month and ranks #3,366,661 among all websites worldwide, #4,407 in Biotechnology and Pharmaceuticals.
- Monthly visits13.6K
▲ 117.8% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,366,661
among all websites
- Category rank#4,407
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.5
- Average visit8 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Corvus Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | View details | ||
| eurekatherapeutics.com | 100% | 1.7K | #7,320,910 | View details | |
| titanpharm.com | 100% | 4.3K | #4,063,501 | View details | |
| mbcbiolabs.com | 98% | #2,013,343 | View details | ||
| nurixtx.com | 97% | 11.5K | #2,207,206 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Corvus Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Corvus Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Corvus Pharmaceuticals
Complete news archive for Corvus Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corvus Pharmaceuticals
Corvus Pharmaceuticals was founded in 2014.
Corvus Pharmaceuticals is headquartered in Burlingame, United States. It is registered at Burlingame, California, United States.
Corvus Pharmaceuticals is a funded company, having raised a total of $87.75M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12.75M, raised on Dec 2014.
Corvus Pharmaceuticals has 31 employees.
Corvus Pharmaceuticals is engaged in the development of novel biopharmaceutical therapies aimed at improving treatments for immune diseases and cancer. The company is based in the biotechnology hub of the San Francisco Bay Area. Its lead program, soquelitinib, is designed as a first-in-class oral therapy to selectively inhibit ITK, modulating critical signaling pathways in the immune system. Research and clinical efforts are directed toward targeting essential cellular elements of the immune system to address unmet medical needs in these sectors.
Corvus Pharmaceuticals's top competitors include Forty Seven, Compass Therapeutics and Pionyr Immuntherapeutics.
Corvus Pharmaceuticals offers Soquelitinib.
Yes, Corvus Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CRVS.
Corvus Pharmaceuticals has 11 investors. Key investors include Fidelity Investments, TD Securities, Orbimed, Rock Springs Capital, and Jennison Associates.
Corvus Pharmaceuticals operates through Corvus Pharmaceuticals, Inc..